Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73)

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease

Anavex Announces Appointment of Dr Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

Anavex Life Sciences Reports Publication of ANAVEX®3-71

Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023